TDO2 and neoplasm: Inhibition of TDO expression diminishes kynurenine production and inactivates the aryl hydrocarbon receptor (AhR), thereby promoting the activation and proliferation of CD3(+) T cells, which contribute to anti-tumor immune responses [84].